LeMaitre doesn’t win much Wall Street favor with record sales in Q2

Thu, 08/01/2013 - 2:29pm
Mass Device

LeMaitre posted record sales and an 8% bump in profits during its 2nd quarter, but saw share prices take a slight hit to close at a loss of nearly 2 points.

LeMaitre Vascular (NSDQ:LMAT) posted an 8% bump in crofts for its 2nd quarter and raised guidance estimates for the year, but Wall Street was less than enthused.

LMAT shares closed at a 1.7% decrease at $6.83 yesterday after the device maker posted record sales during a quarter that CEO George LeMaitre called "excellent."


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.